<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is a highly aggressive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>As Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells are very sensitive to chemotherapy, chemotherapy is the major therapeutic schedule for this disease </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab raised the overall survival rate markedly </plain></SENT>
<SENT sid="3" pm="."><plain>Bone marrow transplant, surgery and radiotherapy also demonstrated to have a supporting role for patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This review focus on research progress of the therapeutics and major regimens for the disease </plain></SENT>
</text></document>